ATEC

Alphatec Holdings reported third quarter 2026 results with total revenue of about US$221 million and a net loss of US$5.47 million, and management now guides full year 2026 revenue to roughly US$862 million, split between US$789 million of surgical revenue…

Alphatec Holdings maintained approximately $882 million in 2026 revenue guidance on August 4, then cut the outlook to approximately $862 million with its third-quarter results. Levi & Korsinsky is investigating on behalf of ATEC shareholders who lost money.

Alphatec slashes its full-year outlook as fewer surgeons have purchased its add-on bone-graft products used for spinal fusion.

Surgical hardware surged 17% as surgeon adoption hit record levels, offsetting biologics weakness.

Key TakeawaysAlphatec fell 36% after third-quarter revenue of $221 million missed its own plan and it cut its 2026 revenue outlook to about $862 million. Cases grew about 20%, so the selloff looks overdone for a shortfall that came down to biologics.

Moby summary of Alphatec Holdings, Inc.'s Q3 2026 earnings call

Alphatec (NASDAQ:ATEC) reported third-quarter revenue growth and expanded profitability, while lowering its full-year outlook to reflect weaker biologics performance, softer thoracolumbar procedure volumes and a temporary international supply constraint.

Alphatec (ATEC) delivered earnings and revenue surprises of -18.18% and -1.38%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

(ATEC) on Thursday reported a loss of $5.On a per-share basis, the Carlsbad, California-based company said it had a loss of 3 cents.